References
- Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44:S2–S8. doi:10.1016/j.semarthrit.2015.04.002.
- Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057. doi:10.1136/rmdopen-2015-000057.
- Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–318. doi:10.1136/annrheumdis-2012-202941.
- Avci AB, Feist E, Burmester G-R. Biologicals in rheumatoid arthritis: current and future. RMD Open. 2015;1(1):e000127. doi:10.1136/rmdopen-2015-000127.
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279. doi:10.1016/j.pharmthera.2007.10.001.
- Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45:124–131. doi:10.1016/j.cyto.2008.11.008.
- Kaymakcalan Z. Beam C and Salfeld J. Murine model for assessing adalimumab, infliximab and etanercept to prevent polyarthritis. Ann Rheum Dis. 2003;62(Suppl 1):136–137.
- Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10:308–315. doi:10.1016/j.coph.2010.01.005.
- Pattacini L, Boiardi L, Casali B, et al. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis. Rheumatology. 2010;49:480–489. doi:10.1093/rheumatology/kep358.
- Benucci M, Saviola G, Manfredi M, et al. Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed. 2012;83:72–80.
- Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Targ Oncol. 2012;7(Suppl S1):S57–S67. doi:10.1007/s11523-011-0196-3.
- Socinski MA, Curigliano G, Jacobs I, et al. Clinical considerations for the development of biosimilars in oncology. MAbs. 2015;7:286–293. doi:10.1080/19420862.2015.1008346.
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417. doi:10.1038/clpt.2011.343.
- McCamish M, Woollett G. The rise of the biosimilar. Expert Rev Clin Pharmacol. 2012;5:597–599. doi:10.1586/ecp.12.60.
- World Health Organization (WHO) Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva [ updated 2009 Oct 19–23; cited 2016 Jan]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
- European Medicines Agency. EMA/CHMP/437/04 guideline on similar biological medicinal products [ updated 2005 Oct; cited Jan 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.
- European Medicines Agency. EMEA/CHMP/BMWP/42832/2005 guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues [ updated 2006 Feb; cited 2016 Jan]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance – non-clinical and clinical issues. Committee for Medicinal Products for Human Use (CHMP). 2015 [cited 2015 Jul 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf.
- US Department of Health and Human Services. Guidance for industry quality considerations in demonstrating biosimilarity to a reference protein product [ updated 2012 Feb; cited 2016 Jan]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2015 [cited 2016 Jan]. Available from: www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
- McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther. 2013;93:315–317. doi:10.1038/clpt.2013.17.
- McCamish M, DaSilva A, Mayer RE, et al. A totality-of-the-evidence approach to the development of GP2015, a proposed etanercept biosimilar. 17th Annual Congress of the European League against Rheumatism; 2016 Jun 8–11; London, UK; Abstract 0321.
- Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs. 2007;67:1211–1241.
- Campa M, Ryan C, Menter A. An overview of developing TNF-α targeted therapy for the treatment of psoriasis. Expert Opin Investig Drugs. 2015;24:1343–1354. doi:10.1517/13543784.2015.1076793.
- Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025–4031.
- Douni E, Sfikakis PP, Haralambous S, et al. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther. 2004;6:R65–R72. doi:10.1186/ar1028.
- European Medicines Agency. Guideline on the investigation of bioequivalence. Committee for Medicinal Products for Human Use (CHMP). 2010 [cited 2016 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
- Enbrel BLA 98-0286. [updated 1998 Nov 2; cited 2015 Mar 17]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm/.
- Enbrel: EPAR – Product Information. Summary of product characteristics [updated 2014 Nov 6; cited 2015 Jan 15]. Available from: http://www.ema.europa.eu/ema/.
- Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527–540. doi:10.1038/nrd3746.
- Beck A, Diemer H, Ayoub D, et al. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. Trends Anal Chem. 2013;48:81–95. doi:10.1016/j.trac.2013.02.014.
- Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16:137–142. doi:10.1517/14712598.2016.1128410.
- Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215–1228. doi:10.1093/rheumatology/keq031.
- Afonso M, Heinrich SS, Poetzl J, et al. Pharmacokinetics and safety of GP2015, a proposed etanercept biosimilar, and etanercept originator product in healthy male subjects: a randomised two-way crossover study. 17th Annual Congress of the European League against Rheumatism; 2016 Jun 8–11; London, UK; Abstract 0145.
- Lee H-H, Song I-H, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486–491. doi:10.1111/j.1365-2133.2007.07682.x.
- Borrás-Blasco J, Navarro-Ruiz A, Borrás C, et al. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009;102:1133–1140. doi:10.1097/SMJ.0b013e3181bb554c.
- Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. Curr Drug Saf. 2006;1:259–264.